33469-14-6

Usage

Uses

Used in Pharmaceutical Development:
1H-Imidazole, 2-(3-chlorophenyl)-5-(trifluoroMethyl) is used as a potential candidate in pharmaceutical development for its possible biological activities. The presence of the imidazole ring and the substituted groups may contribute to its efficacy in treating various medical conditions, warranting further research and development in the field of medicinal chemistry.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1H-Imidazole, 2-(3-chlorophenyl)-5-(trifluoroMethyl) is used as a subject of research to explore its potential applications. 1H-IMidazole, 2-(3-chlorophenyl)-5-(trifluoroMethyl)'s unique structure and the possibility of various biological activities make it a valuable target for investigation, potentially leading to the discovery of new drugs and therapeutic agents.

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 

Downstream Products

• 97749-78-5 2-(3-chlorophenyl)-1H-4-imidazolcarbaldehyde 
• 81654-09-3 4-Bromo-2-(3-chlorophenyl)-5-trifluoromethylimidazole 

Relevant academic research and scientific papers

Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD)

A series of 2-Aryl-4-Bis-amide Imidazoles (ABAI-1 to 30) were designed as anti-inflammatory agents. These compounds were synthesized and evaluated for the in vitro anti-inflammatory activities (inhibition of NO production and release of inflammatory cytok

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

Synthesis, structure, and neuroprotective properties of novel imidazolyl nitrones

A new series of imidazolyl nitrones spin traps has been synthesized and evaluated pharmacologically. The salient structural feature of these molecules is the presence of an imidazole moiety substituted by aromatic or heteroaromatic cycles. This connectivi

Herbicidal substituted imidazoles

This invention relates to novel substituted imidazoles of the formula: STR1 wherein R1 is a trifluoromethyl group, a halogen atom, an unsubstituted aryl group, a substituted aryl group, a heteroaromatic group, or a substituted heteroaromatic gr

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

2-Pyrazinyl-trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.